Liver Injury, Vanishing Bile Duct Syndrome, and Death

The Tavneos lawsuit involves claims that the manufacturer failed to adequately warn patients and physicians that Tavneos (avacopan) can cause serious drug-induced liver injury, vanishing bile duct syndrome, liver failure, and death. The FDA identified 76 cases of Tavneos-related liver injury in postmarketing data, including 54 hospitalizations and 8 deaths, and issued a safety alert on March 31, 2026. Lawsuits allege that patients and doctors were not warned about these risks, particularly vanishing bile duct syndrome, which was not identified in the original labeling.

You may be able to sue if you took Tavneos and developed drug-induced liver injury, vanishing bile duct syndrome, liver failure, or another serious hepatic condition, and your medical records document that injury. Eligibility generally depends on the severity of the harm, whether the condition required hospitalization or specialist care, and your state’s filing deadline. An attorney can evaluate your records at no cost to determine whether you have a viable claim.

Tavneos has not been formally recalled or removed from the market as of June 2026. The FDA proposed withdrawing approval of Tavneos on April 27, 2026, citing concerns about clinical trial data integrity and hepatotoxicity risks, and Amgen had until June 1, 2026, to request a formal hearing on that proposal [VERIFY: confirm hearing request status]. The FDA’s March 31, 2026, safety communication identified serious liver injuries and deaths, but did not mandate removal. Tavneos remains available by prescription while the regulatory process continues.

Vanishing bile duct syndrome (VBDS) is a rare and severe liver condition characterized by progressive destruction and disappearance of the bile ducts inside the liver. When bile ducts are destroyed, bile cannot flow properly, leading to a buildup that damages liver tissue and can cause permanent liver damage or failure. VBDS associated with Tavneos typically presented with jaundice, severe itching, and elevated liver enzymes, with the majority of cases occurring within 60 days of starting treatment and primarily affecting patients aged 65 and older. The FDA identified VBDS as a new safety concern not disclosed in Tavneos’s original labeling.

Symptoms of Tavneos-related liver injury include yellowing of the skin or eyes (jaundice), severe itching, unusual fatigue, nausea or vomiting, dark urine, light-colored stools, pain or swelling in the upper right abdomen, and elevated liver enzyme results on blood tests. These symptoms may indicate drug-induced liver injury or vanishing bile duct syndrome. The FDA advises that patients who experience these symptoms while taking Tavneos contact their healthcare provider immediately. Anyone who has already stopped Tavneos and developed these symptoms should also seek medical care, as liver damage can continue after the drug is discontinued.

No. As of June 2026, there is no multidistrict litigation (MDL) or class action lawsuit for Tavneos personal injury claims involving liver damage. A separate securities fraud class action was previously filed against ChemoCentryx by investors over allegations related to clinical trial data; that case settled for $35 million in March 2026 and involved investor claims rather than patient injuries. Tavneos liver injury claims are currently being filed and investigated as individual product liability lawsuits. If enough cases are filed, consolidation into an MDL could follow, but that has not occurred yet.

The filing deadline for a Tavneos lawsuit depends on your state’s statute of limitations, which typically ranges from two to three years for personal injury claims. Most states apply the discovery rule, which starts the clock on the date you knew or reasonably should have known that Tavneos caused your liver injury, rather than the date you first took the drug. For wrongful death claims, the deadline generally runs from the date of death. Because deadlines vary and missing one can permanently bar your claim, having your case reviewed as soon as possible is the safest course.

The FDA has taken two significant actions regarding Tavneos in 2026. On March 31, 2026, the agency issued a Drug Safety Communication identifying 76 cases of serious drug-induced liver injury associated with Tavneos, including 54 hospitalizations and 8 deaths, and flagging vanishing bile duct syndrome as a new safety concern. On April 27, 2026, the FDA proposed withdrawing approval of Tavneos entirely, citing a lack of substantial evidence of effectiveness and untrue statements in the original approval application. Amgen, which markets Tavneos through its ChemoCentryx subsidiary, declined the FDA’s earlier January 2026 voluntary withdrawal request, and Tavneos remains on the market while the regulatory process continues.

Family members may be able to file a wrongful death lawsuit if a loved one died after developing drug-induced liver injury, vanishing bile duct syndrome, or liver failure associated with Tavneos. Wrongful death claims are filed by surviving spouses, children, or other eligible family members, depending on state law. The deadline for wrongful death claims typically runs from the date of death rather than the date of drug use. A free case evaluation can help the surviving family determine whether they have a viable claim and how much time they have to file.

No settlement amounts have been established for Tavneos personal injury claims, because the litigation is in early stages and no MDL or global resolution process exists yet. The value of an individual claim depends on the severity of the liver injury, the cost of medical care and hospitalization, lost income, long-term effects, and, for wrongful death claims, the financial support the deceased provided to family members. In comparable pharmaceutical failure-to-warn cases involving serious organ injury, individual settlements have ranged widely based on these factors. An attorney can estimate a value range after reviewing your specific records.